{"title":"[Anti-inflammatory therapeutic advances in nephrology: can we learn from cardiology?]","authors":"Laura Katharina Sievers, Roland Schmitt","doi":"10.1055/a-2376-0783","DOIUrl":null,"url":null,"abstract":"<p><p>Pathophysiology of kidney diseases frequently implies sterile inflammation, e.g. during glomerulonephritis or after renal transplantation. Recently, the relevance of systemic low-grade inflammation for chronic kidney disease (CKD) progression and complications of CKD have come into focus. In this review article, the etiology, and consequences of low-grade inflammation in CKD patients are discussed. Further, the potential of anti-inflammatory approaches to slow down CKD progression is addressed. Recent advances have resulted in FDA approval of colchicine for patients with preserved renal function and atherosclerosis. Thus, lastly, anti-inflammatory therapy of atherosclerosis in patients with or without CKD is outlined.Taken together, anti-inflammatory therapy offers novel opportunities to improve CKD progression, inhibit transition from acute to chronic kidney disease and reduce the risk of fatal long-term complications such as cardiovascular disease.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"150 6","pages":"293-297"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche medizinische Wochenschrift (1946)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2376-0783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
[Anti-inflammatory therapeutic advances in nephrology: can we learn from cardiology?]
Pathophysiology of kidney diseases frequently implies sterile inflammation, e.g. during glomerulonephritis or after renal transplantation. Recently, the relevance of systemic low-grade inflammation for chronic kidney disease (CKD) progression and complications of CKD have come into focus. In this review article, the etiology, and consequences of low-grade inflammation in CKD patients are discussed. Further, the potential of anti-inflammatory approaches to slow down CKD progression is addressed. Recent advances have resulted in FDA approval of colchicine for patients with preserved renal function and atherosclerosis. Thus, lastly, anti-inflammatory therapy of atherosclerosis in patients with or without CKD is outlined.Taken together, anti-inflammatory therapy offers novel opportunities to improve CKD progression, inhibit transition from acute to chronic kidney disease and reduce the risk of fatal long-term complications such as cardiovascular disease.